Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

NCT04509700 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04509700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04509700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 3, 2020
Completion date
November 5, 2026
Enrollment
112 (actual)
Sites
105

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell malignancies